MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

MDT

88.65

+1.69%↑

VEEV

282.96

-1.55%↓

A

120.24

+1.92%↑

HQY

102.79

-1.67%↓

PHR.US

28.46

+0.21%↑

Search

Arcus Biosciences Inc

Cerrado

SectorSalud

8.35 2.58

Resumen

Variación precio

24h

Actual

Mínimo

7.88

Máximo

8.6

Métricas clave

By Trading Economics

Ingresos

-18M

-112M

Ventas

2M

28M

BPA

-1.14

Margen de beneficio

-400

Empleados

627

EBITDA

-34M

-122M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+210.69% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-104M

862M

Apertura anterior

5.77

Cierre anterior

8.35

Noticias sobre sentimiento de mercado

By Acuity

67%

33%

342 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Arcus Biosciences Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

1 jul 2025, 23:09 UTC

Ganancias

Constellation Brands 1Q Profit, Sales Decline Amid Softer Consumer Demand -- Update

1 jul 2025, 19:16 UTC

Adquisiciones, fusiones, absorciones

Sabadell Seeks Shareholder Approval of Nearly $4 Billion Sale of U.K. Unit to Santander

1 jul 2025, 23:47 UTC

Charlas de Mercado

Nikkei May Fall Amid U.S. Tariff Uncertainty -- Market Talk

1 jul 2025, 23:41 UTC

Charlas de Mercado

Gold Steady, Underpinned by U.S. Fiscal-Deficit Concerns -- Market Talk

1 jul 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

James Hardie: Deal Represents Implied Value of $8.4 Billion

1 jul 2025, 22:23 UTC

Adquisiciones, fusiones, absorciones

James Hardie: Cash and Stock Deal Implies $54.18 Per AZEK Share

1 jul 2025, 22:21 UTC

Adquisiciones, fusiones, absorciones

James Hardie Completes Acquisition of AZEK

1 jul 2025, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jul 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 jul 2025, 20:24 UTC

Ganancias

Constellation Brands Earnings Miss as Consumers Cool on Alcohol -- Barrons.com

1 jul 2025, 19:55 UTC

Charlas de Mercado

Oil Futures Resume Cautious Rally -- Market Talk

1 jul 2025, 19:27 UTC

Charlas de Mercado

U.S. Natural Gas Futures Lose More Ground -- Market Talk

1 jul 2025, 19:12 UTC

Charlas de Mercado

Dollar Little Changed as Tax-And-Spending Bill Advances -- Market Talk

1 jul 2025, 19:01 UTC

Adquisiciones, fusiones, absorciones

Sabadell Seeks Shareholder Approval of Nearly $4B Sale of U.K. Unit to Santander

1 jul 2025, 18:41 UTC

Adquisiciones, fusiones, absorciones

How DexCom, Insulet, and Amedisys Might Be Affected by Medicare Cuts -- Barrons.com

1 jul 2025, 18:33 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

1 jul 2025, 18:33 UTC

Charlas de Mercado

Gold Gains as Investors Look Ahead on Budget Bill -- Market Talk

1 jul 2025, 18:32 UTC

Charlas de Mercado

Mexico Manufacturing PMIs Remain Weak in June -- Market Talk

1 jul 2025, 18:22 UTC

Charlas de Mercado

Remittances to Mexico Down in May -- Market Talk

1 jul 2025, 17:45 UTC

Charlas de Mercado

Seasonal Demand Supports Further Oil Gains -- Market Talk

1 jul 2025, 17:01 UTC

Adquisiciones, fusiones, absorciones

Danone Completed Acquisition of Majority Stake in Kate Farms

1 jul 2025, 16:55 UTC

Ganancias

10 European Dividend Stocks That Could Beat Their U.S. Counterparts -- Barrons.com

1 jul 2025, 16:27 UTC

Charlas de Mercado

Trade Concerns Ease in Bank of Mexico Survey -- Market Talk

1 jul 2025, 16:25 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Home Depot's GMS Buy Unlocks New Vertical Adjacent to SRS -- Market Talk

1 jul 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

1 jul 2025, 15:48 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Home Depot's Offer for GMS Unlikely to Be Beat -- Market Talk

1 jul 2025, 15:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

1 jul 2025, 15:46 UTC

Charlas de Mercado

Amazon Seen With Improved Logistics Ahead of Longer Prime Day -- Market Talk

1 jul 2025, 14:54 UTC

Charlas de Mercado

Thales Expected to Stick to This Year's Sales Guidance -- Market Talk

1 jul 2025, 14:49 UTC

Charlas de Mercado

Platinum Prices Extend Rally on China Demand, Supply Worries -- Market Talk

Comparación entre iguales

Cambio de precio

Arcus Biosciences Inc Esperado

Precio Objetivo

By TipRanks

210.69% repunte

Estimación a 12 meses

Media 25.29 USD  210.69%

Máximo 46 USD

Mínimo 12 USD

De acuerdo con 9 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arcus Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

9 ratings

8

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.01 / 8.75Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Neutral Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

342 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.